VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb
-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation - CAMPBELL, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the
View HTML
Toggle Summary VIVUS Announces 1-for-10 Reverse Stock Split
CAMPBELL, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018 , the Company will enact a 1-for-10 reverse stock split of its
View HTML
Toggle Summary VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia®
-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a
View HTML
Toggle Summary VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018
CAMPBELL, Calif. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that
View HTML
Toggle Summary VIVUS Reports Second Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS Appoints Kenneth Suh as President
CAMPBELL, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President.  Previously, Mr. Suh was President and CEO of Willow Biopharma Inc.
View HTML
Toggle Summary VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018
CAMPBELL, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August 7, 2018. The company will host a conference call beginning
View HTML
Toggle Summary VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension- CAMPBELL, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive
View HTML
Toggle Summary VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction
CAMPBELL, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S.
View HTML
Toggle Summary VIVUS Reports First Quarter 2018 Financial Results
  VIVUS Reports First Quarter 2018 Financial Results     Company provides business update on PANCREAZE ® acquisition,  new Athyrium debt line and new management Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS ) (the
View HTML